The endocrine cell's resting state is an actively maintained G1 restraint, and menin is what maintains it
also called menin-dependent endocrine quiescence · p27/p18-enforced endocrine G1
Hormone-producing cells are not idle by default - they are actively held still, by brake proteins whose genes menin keeps switched on. Remove menin and the brakes come off; that is what a menin-blocking drug does, and in the pancreas it is being developed deliberately as a way to regrow insulin cells.
The same thing, for a scientist
The non-proliferative state of endocrine cells is maintained, not passive: menin keeps CDKN1B (p27Kip1) and CDKN2C (p18INK4c) transcribed by recruiting MLL to their promoters and coding regions [E1], and in vivo that maintenance is chromatin-level, with menin at the p27 and p18 promoters raising H3 lysine 4 methylation and the mark reduced in Men1-mutant islet tumours [E2]. The state is reversible and physiologically regulated - pregnancy and prolactin lower islet menin and beta cells proliferate [E3] - and it is pharmacologically reversible, since a menin-MLL inhibitor plus a TGF-beta inhibitor drives replication of primary human beta cells through down-regulation of CDKN1A, CDKN1B and CDKN2C [E4]. Named as a cell state because it is the endocrine counterpart of HSC quiescence, because the PI's cell-state dimension is exactly what makes gene-men1's endocrine-paradox section checkable, and because a state that a drug releases on purpose in one indication is the same state it releases by accident in another.
What defines the state
| feature | value |
|---|---|
| cell-cycle position | G1 / out of cycle, reversibly |
| molecular enforcers | p27Kip1 (CDKN1B), p18INK4c (CDKN2C) 12 |
| how they are kept on | menin recruits MLL to their promoters and coding regions; menin raises H3K4 methylation there in vivo 12 |
| physiological release | pregnancy and prolactin lower islet menin; beta cells proliferate 3 |
| pharmacological release | MI-2 plus a TGF-beta inhibitor drives primary human beta-cell replication via CDKN1A/1B/2C down-regulation 4 |
| what release costs | in Men1-null mice, islet tumours, on a timescale of roughly 60 weeks |
The last two rows are the same molecular event at different durations, which is the whole of the endocrine-safety argument compressed into one table.
Why this is the checkable form of the endocrine paradox
gene-men1 presents the paradox as a puzzle about one protein having two jobs, and answers it with four arguments for manageability and one against. All five are about exposure - separability of the drug pocket, TGF-beta routing, latency, tissue expression, the label's PTH signal.
Naming the state instead makes the question mechanical: is the endocrine cell's G1 restraint released at a marrow-efficacious exposure, and if so how far and for how long? That has a measurable answer in three tissues, one of which (beta cell) already has one in the affirmative 4. It converts an argument about plausibility into a pharmacodynamic measurement, which is what exp-paired-endocrine-and-marrow-readout-under-a-menin-inhibitor is for.
The parathyroid hole
Every measurement above is islet or cultured cell. The tissue with the clinical signal - intact PTH increased in 34% of 241 patients on the revumenib label - has no experimental measurement of any kind under a menin inhibitor (absence-nothing-has-ever-been-measured-in-parathyroid-under-a-menin-inhibitor).
So this state is characterised in the tissue where releasing it is being pursued as a therapy, and uncharacterised in the tissue where releasing it is the known adverse effect. That asymmetry is not anybody's fault; it is where the funding is. It does mean the graph should stop extrapolating from islet to parathyroid without saying so.
| state class | reversible G1 restraint, actively maintained |
|---|---|
| maintained by | menin-directed MLL recruitment and H3K4 methylation at those promoters |
| release physiological | pregnancy, prolactin, high glucose (the last via mechanism-menin-is-a-reversible-physiological-brake-on-beta-cells) |
| release pharmacological | MI-2 plus TGF-beta inhibition in human beta cells, CDKN1A/1B/2C down (PMID 32646642) |
| counterpart state in blood | cell-state-hsc-quiescence-maintained-by-mll1 - also actively maintained, also by an MLL1-dependent programme, and with the opposite consequence when released |
| shown for fusion | NO, and it should not be. This is normal endocrine tissue. Its relevance to the fusion is entirely as the off-target compartment of the drug. |
enforcers
[ "CDKN1B (p27Kip1)", "CDKN2C (p18INK4c)" ]
tissues characterised
[ "pancreatic islet / beta cell (mouse in vivo and human ex vivo)", "pituitary (expression only)" ]
tissues uncharacterised
[ "parathyroid - no measurement of any kind under a menin inhibitor" ]
- A drug company is deliberately developing menin inhibition to release this state in the beta cell for diabetes. The same release in the parathyroid is the labelled adverse reaction of the leukaemia drug. The therapeutic and the toxic use are the same intervention on the same state in two glands.
- Because the state is reversible, short exposures look safe and the risk is a function of duration - which means the relapsed-refractory population that generates all the current safety data is the population least able to reveal it.
- Is the parathyroid chief cell's resting state maintained the same way? p27 and p18 are the enforcers in islet; nothing establishes them as the enforcers in parathyroid, and the graph currently assumes it.
- Does the state's release saturate? Pregnancy releases it partially and reversibly over weeks; a drug releases it continuously for months. Nothing measures whether the proliferative response plateaus or accumulates, and that distinction is the whole of the neoplasia risk.
- Is there a state marker that can be read in a patient? Serum intact PTH is a secretion readout, not a cell-state readout. If endocrine CDKN1B has a circulating proxy, the liability becomes monitorable; nobody has looked.
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Menin activates transcription of p27Kip1 and p18Ink4c by recruiting MLL to their promoters and coding regions, and loss of function of either MLL or menin down-regulates both and deregulates cell growth.
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. · Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL · Proc Natl Acad Sci U S A 2005What this evidence cannot show
Cell lines and transfection, not endocrine tissue; abstract read, full text not opened.
Evidence that argues against this (1)
- The pharmacological test of this mechanism does not always reproduce it: in osteosarcoma a menin inhibitor suppressed H3K4 methylation and RAISED p27. If the transcriptional model were as direct as this paper's promoter work implies, that experiment should not have been possible in the direction it went. Tian S et al. 2025
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In vivo, expression of CDK inhibitors including p27 and p18 is disrupted in mouse islet tumours lacking menin; menin associates directly with regions of the p27 and p18 promoters and increases H3 lysine 4 methylation there; and that methylation is reduced at both loci in islet tumours from Men1 mutant mice.
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. · Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK · Proc Natl Acad Sci U S A 2005What this evidence cannot show
Mouse islet tumours rather than normal islets, so the reduced mark may be a consequence of transformation as well as a cause; methylation state not resolved to me1/me2/me3; abstract read, full text not opened.
Evidence that argues against this (1)
- The mark was measured in islet TUMOURS, so reduced H3K4 methylation at p27 and p18 may be a consequence of transformation rather than the proximate effect of menin loss. A normal-islet time course after acute menin removal, which this paper does not report, would separate the two - and the pharmacological arm in human beta cells reports only transcript, not chromatin. Pahlavanneshan S et al. 2020
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Pregnancy stimulates proliferation of maternal islet beta cells accompanied by reduced islet menin and reduced menin targets; transgenic menin expression in maternal beta cells prevents islet expansion and produces hyperglycaemia and impaired glucose tolerance; and prolactin represses islet menin and stimulates beta-cell proliferation.
Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. · Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH, Kim SK · Science 2007What this evidence cannot show
Mouse; abstract read, full text not opened. Already cited in six entries of this corpus, notably mechanism-menin-is-a-reversible-physiological-brake-on-beta-cells, which treats it in more depth than this entry does; it is here to establish that the state is physiologically reversible, not to re-derive that conclusion.
Evidence that argues against this (1)
- Pregnancy lowers menin only partially and transiently. A drug lowers it continuously for months, and the mouse genetics say full biallelic loss plus additional events plus roughly 60 weeks produces tumours - so the reversibility demonstrated here is evidence about a physiological release and does not transfer to a pharmacological one. The parathyroid arm of that question has no measurement at all. Brown MR et al. 2025
- E4strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In primary human pancreatic beta cells, the menin-MLL interaction inhibitor MI-2 with TGF-beta signalling inhibitors synergistically increased ex vivo replication without affecting insulin production, cooperating through down-regulation of CDKN1A, CDKN1B and CDKN2C.
Combined inhibition of menin-MLL interaction and TGF-beta signaling induces replication of human pancreatic beta cells. · Pahlavanneshan S, Behmanesh M, Oropeza D, Furuyama K, Tahamtani Y, Basiri M, Herrera PL, Baharvand H · Eur J Cell Biol 2020What this evidence cannot show
Ex vivo donor islets over days; MI-2 is an early tool compound and not a clinical molecule; transcript-level, no chromatin readout. Abstract read, full text not opened. Already cited twice in this corpus.
Evidence that argues against this (1)
- In osteosarcoma a menin inhibitor suppressed H3K4 methylation and RAISED p27, the opposite direction. Non-endocrine tissue, and the rise co-occurs with apoptosis, but it is the only other pharmacological measurement of this axis and the two disagree in sign. Tian S et al. 2025
menin maintains the endocrine cell's reversible G1 restraint through CDKN1B and CDKN2C
the molecular mechanism that maintains the state
the physiological release of the same state
- related to →Menin inhibition makes adult human beta cells divide in a dish - the hardest thing in beta-cell biology
the pharmacological release of the same state
the same architecture in blood - an actively maintained resting state under MLL1 control - with the opposite consequence on release
the endocrine half of the two-address-list claim